Webcast Alert: Cavco Industries, Inc. Announces Fiscal 2024 Fourth Quarter and Year End Earnings Release and Conference Call Webcast
15 mai 2024 20h50 HE
|
Cavco Industries, Inc.
PHOENIX, May 15, 2024 (GLOBE NEWSWIRE) -- Cavco Industries, Inc. (Nasdaq: CVCO) will release earnings for the fourth quarter and fiscal year ended March 30, 2024 on Thursday, May 23, 2024 after the...
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
14 mai 2024 07h00 HE
|
Optinose, Inc.
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million ...
Nano Dimension Announces Q1/2024 Conference Call to Discuss Quarterly Results
13 mai 2024 08h00 HE
|
Nano Dimension Ltd.
Participants Are Welcome to Listen June 3rd at 9:00 am ET Waltham, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading...
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
10 mai 2024 14h56 HE
|
Optinose, Inc.
YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
CytoSorbents Reports First Quarter 2024 Results
09 mai 2024 16h17 HE
|
CytoSorbents
CytoSorbents Reports First Quarter 2024 Results
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
08 mai 2024 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Arbutus to Participate in Two Upcoming Investor Conferences
07 mai 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2024 sowie Informationen zur Geschäftsentwicklung
06 mai 2024 06h45 HE
|
BioNTech SE
BioNTech ist auf einem gutem Weg, das Jahresziel von zehn oder mehr potenziell zulassungsrelevanten Studien in der Pipeline bis Ende 2024 zu erreichen: weitere Phase-3-Studie mit der Behandlung der...
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
06 mai 2024 06h45 HE
|
BioNTech SE
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low...
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
03 mai 2024 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...